Grail's Revenue Growth Impresses Amid Proxy Fight.

Illumina CEO Francis deSouza has praised the company's acquisition of Grail after the cancer test developer's revenue doubled in the last year. Grail's early screening test, which can detect over 50 types of cancer through a single blood draw, has driven the sales. However, the acquisition is the focus of a proxy fight with activist investor Carl Icahn, who has called it "disastrous" and criticized Illumina's corporate governance. Antitrust regulators in the US and Europe have also ordered Illumina to divest the $7.1 billion acquisition.